Alkermes CEO Pops stays focused on 5461 filing plans; Shkreli gets booed at Harvard
• Alkermes $ALKS is moving ahead with plans to file a new depression drug, ALKS-5461, later in the year. “This is a fast-track designated medicine …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
